AcceleraTED Collect
Accelerated Translation of therapeutic agents and Emerging Devices in Head and Neck and Thyroid cancer - Collection of tissue
Acronym
AcceleraTED Collect
Summary
The aim of this trial is to characterise the nature and function of T cell, antibody responses and mechanisms of carcinogenesis (including genomics and methylation) within HPV+ and HPV- head and neck cancer patients, with a view to providing crucial information towards developing immunotherapeutic and other treatment strategies.
Eligibility
Inclusion Criteria:
• Participants undergoing biopsy or surgery for potential or confirmed head and neck cancer
• Participants undergoing biopsy or surgery for potential or confirmed cervix, colorectal, lung, oesophageal, breast, prostate, bladder, uterus (control cancers)
• Participants undergoing biopsy or surgery for benign head and neck conditions – mainly tonsillectomy, examination of upper aero-digestive tract under anaesthetic (normal controls)
• Age – 18 to 70 years
• Patient has given written informed consent
Exclusion Criteria:
• Patients less than 18 years old
• Patients with severe anaemia who would be disadvantaged clinically if they gave blood
• Patients with known immunodeficiency syndromes e.g. HIV
• Patients unable to give informed consent e.g. Patients with severe mental disability or vulnerable adults
Principal investigators /study co-odinators:
Dr. Steven P. Lee (ImmuGen Immunology Coordinator)
Senior Cancer Research Fellow
School of Cancer Sciences
University of Birmingham
Vincent Drive, Edgbaston
Birmingham B15 2TT
Telephone: +44 (0)121 414 2803
Email: S.P.LEE@bham.ac.uk
Fax: +44 (0)121 414 486
